Author Archives: Gastroenterology Journal
Is selectivity the JAKpot winner for IBD treatment?
Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
The POISE randomized double-blind placebo-controlled trial demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes (ALP, bilirubin, AST, ALT) in patients with primary biliary cholangitis (PBC). The objectiv… Continue reading
A Tale of Two Fibres: a Liver Twist!
AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review
The purpose of this expert review is to summarize the diagnosis and management of refractory celiac disease. It will review evaluation of patients with celiac disease who have persistent or recurrent symptoms, differential diagnosis, nutritional suppor… Continue reading
Minimal risk of drug-induced liver injury with molnupiravir and ritonavir-boosted nirmatrelvir
Inflammatory Bowel Disease is Associated with Prediagnostic Perturbances in Metabolic Pathways
Th17 cell-derived amphiregulin promotes colitis-associated intestinal fibrosis through activation of mTOR and MEK in intestinal myofibroblasts
Intestinal fibrosis is a significant complication of Crohn’s disease (CD). Gut microbiota reactive Th17 cells are crucial in the pathogenesis of CD; however, how Th17 cells induce intestinal fibrosis is still not completely understood. Continue reading
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma
Single agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown. To fill this gap, we he… Continue reading